Amlodipine (Dihydropyridine CCB)
Treatment for Hypertensive Heart Disease
Typical Dosage: 2.5mg - 10mg daily
Effectiveness
86%
Safety Score
70%
Clinical Trials
2
Participants
800K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
2.5mg - 10mg daily
Time to Effect
1-2 weeks for full BP effect, months for cardiac remodeling
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
20(Treat 20 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
94%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40
Monitoring:$300
Side Effect Mgmt:$75
Total Annual:$415
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$22,000/QALY
QALYs Gained
2.3
Outcome-Based Costs
Cost per Responder
$532.05
Comparison vs Lisinopril (ACE Inhibitor)
Cost Difference
+$10/year
More expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Amlodipine (Dihydropyridine CCB) Outcomes
for Hypertensive Heart Disease
Efficacy Outcomes
Overall Effectiveness
+86%
Response Rate
+78%
Common Side Effects
Peripheral edema
+15%
Headache
+8%
Flushing
+5%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Amlodipine (Dihydropyridine CCB) in Hypertensive Heart Disease
Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)
NCT00294567COMPLETEDPHASE4
199 participants
INTERVENTIONAL
Tokyo, Japan
Started: Dec 1, 2005
Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
NCT00129233COMPLETEDPHASE4
1.15K participants
INTERVENTIONAL
Nagoya, Japan
Started: Oct 1, 2004